[go: up one dir, main page]

SG10201912688YA - A method of treatment - Google Patents

A method of treatment

Info

Publication number
SG10201912688YA
SG10201912688YA SG10201912688YA SG10201912688YA SG10201912688YA SG 10201912688Y A SG10201912688Y A SG 10201912688YA SG 10201912688Y A SG10201912688Y A SG 10201912688YA SG 10201912688Y A SG10201912688Y A SG 10201912688YA SG 10201912688Y A SG10201912688Y A SG 10201912688YA
Authority
SG
Singapore
Prior art keywords
treatment
Prior art date
Application number
SG10201912688YA
Inventor
Der Weerden Nicole Louise Van
Marilyn Anne Anderson
Original Assignee
Hexima Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201912688Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hexima Ltd filed Critical Hexima Ltd
Publication of SG10201912688YA publication Critical patent/SG10201912688YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
SG10201912688YA 2014-10-21 2015-05-29 A method of treatment SG10201912688YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462066808P 2014-10-21 2014-10-21

Publications (1)

Publication Number Publication Date
SG10201912688YA true SG10201912688YA (en) 2020-02-27

Family

ID=55748162

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912688YA SG10201912688YA (en) 2014-10-21 2015-05-29 A method of treatment
SG11201703184SA SG11201703184SA (en) 2014-10-21 2015-05-29 A method of treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201703184SA SG11201703184SA (en) 2014-10-21 2015-05-29 A method of treatment

Country Status (24)

Country Link
US (4) US9713632B2 (en)
EP (2) EP3949977A1 (en)
JP (3) JP6646662B2 (en)
KR (1) KR102472312B1 (en)
CN (3) CN113368215A (en)
AU (2) AU2015336933B2 (en)
BR (1) BR112017008211A2 (en)
CA (1) CA2965187A1 (en)
CY (1) CY1124640T1 (en)
DK (1) DK3209319T3 (en)
ES (1) ES2890461T3 (en)
HR (1) HRP20211477T8 (en)
HU (1) HUE056178T2 (en)
LT (1) LT3209319T (en)
MX (2) MX382906B (en)
MY (1) MY186552A (en)
NZ (1) NZ731143A (en)
PL (1) PL3209319T3 (en)
PT (1) PT3209319T (en)
RS (1) RS62386B1 (en)
SG (2) SG10201912688YA (en)
SI (1) SI3209319T1 (en)
SM (1) SMT202100558T1 (en)
WO (1) WO2016061619A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573980B2 (en) 2013-03-15 2017-02-21 Spogen Biotech Inc. Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
JP2017517498A (en) * 2014-04-24 2017-06-29 ヘキシマ リミテッド Drugs and treatment methods
IL315468A (en) 2014-09-17 2024-11-01 Spogen Biotech Inc Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
PL3209319T3 (en) * 2014-10-21 2021-12-20 Hexima Limited A method of treatment of fungal infections
CA2987669A1 (en) * 2015-05-29 2016-12-08 Hexima Limited A method of in vivo treatment
EP3684168A4 (en) 2017-09-20 2021-10-27 Spogen Biotech Inc. Fusion proteins, recombinant bacteria, and exosporium fragments for plant health
US12053486B2 (en) 2018-03-09 2024-08-06 Therazure LLC Compositions for the treatment of infections in feet

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3298368A (en) 1964-04-24 1967-01-17 Charos Peter Heated cream applicator gloves
US4087675A (en) 1977-02-07 1978-05-02 Coretta Sansonetti Heated mitten
US4241080A (en) * 1979-05-29 1980-12-23 The Dow Chemical Company Stabilized aqueous antimicrobial composition
US4267852A (en) 1979-09-17 1981-05-19 Hullinger Judith E Process for enhancing and strengthening the growth of nails
JPS5775663A (en) 1980-07-22 1982-05-12 Kiichirou Sarui Apparatus for treating dermatophytosis
US5181914A (en) 1988-08-22 1993-01-26 Zook Gerald P Medicating device for nails and adjacent tissue
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5098415A (en) 1990-10-09 1992-03-24 Jack Levin Device and method for using an aqueous solution containing ozone to treat foot diseases
US5156591A (en) 1990-12-13 1992-10-20 S. I. Scientific Innovations Ltd. Skin electrode construction and transdermal drug delivery device utilizing same
JPH0657323A (en) 1992-08-06 1994-03-01 Sumitomo Metal Ind Ltd Burner control method in heating furnace
JPH0728521A (en) 1993-07-09 1995-01-31 Yaskawa Electric Corp Simulation program automatic creation method
US5449658A (en) 1993-12-07 1995-09-12 Zeneca, Inc. Biocidal compositions comprising polyhexamethylene biguanide and EDTA, and methods for treating commercial and recreational water
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5668084A (en) 1995-08-01 1997-09-16 Zeneca Inc. Polyhexamethylene biguanide and surfactant composition and method for preventing waterline residue
US5795314A (en) 1996-06-19 1998-08-18 Berenstein; Moshe Therapeutic fingernail treatment device
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US5981698A (en) * 1997-06-03 1999-11-09 Cyberchemics, Inc. Antimicrobial polypeptides
US5993790A (en) * 1997-08-04 1999-11-30 Pedinol Pharmacal Inc. Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
WO1999009997A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
US6727401B1 (en) 1998-02-12 2004-04-27 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6235047B1 (en) 1998-04-06 2001-05-22 Augustine Medical, Inc. Wound treatment apparatus with a heater, a heat conductive bandage, and heat-spreading means acting between the heater and bandage
US6572580B2 (en) 1998-08-06 2003-06-03 Profoot, Inc. Set depth nail notcher with patch system and method for treating nail fungus
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US6477410B1 (en) 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
AU6076200A (en) 1999-07-08 2001-01-30 Johnson & Johnson Consumer Companies, Inc. Exothermic bandage
US6528697B1 (en) 2000-01-03 2003-03-04 Augustine Medical, Inc. Modular bandage
US6281239B1 (en) 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
CN101029308B (en) * 2001-02-08 2012-07-25 赫希玛有限公司 Plant derived molecule, genetic coding sequence and its uses
US6585963B1 (en) 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US6881418B2 (en) 2001-06-08 2005-04-19 K.I Chemical Industry Co., Ltd. Liquid deodorant killing microorganism and method of microorganism-killing deodorization
EP2270165A3 (en) * 2001-06-22 2011-09-07 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
US6821508B2 (en) 2001-06-27 2004-11-23 Rutgers, The State University Composition and method for topical nail treatment
JP2003123136A (en) 2001-10-17 2003-04-25 Toshiba Electric Appliance Co Ltd Beverage serving device
US20030144625A1 (en) 2002-01-28 2003-07-31 Garry Sherman Method and apparatus for the treatment of infections of the nail matrix and nail plate
US6634367B2 (en) 2002-03-25 2003-10-21 Kathleen Hunter Abraham Sealing enclosure for finger tips
US6846837B2 (en) 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US8486426B2 (en) 2002-07-29 2013-07-16 Kimberly-Clark Worldwide, Inc. Methods and compositions for treatment of dermal conditions
US6921529B2 (en) 2002-07-29 2005-07-26 Joseph C. Maley Treatment modality and method for fungal nail infection
US20070292355A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US20040161452A1 (en) 2003-02-18 2004-08-19 Petit Michael G. Drug-dispensing dressing and composition for treating onychomycosis
CA2532786A1 (en) 2003-07-14 2005-01-20 Power Paper Ltd. Method, apparatus, and kit for onychomycosis treatment using electrokinetic transport of substances
US20050261755A1 (en) 2004-05-24 2005-11-24 Bacino John E Conformable heat transfer pack
US20060013862A1 (en) 2004-07-19 2006-01-19 Held Jerry M Onychomycosis: a new process for cure
JP2006075357A (en) 2004-09-09 2006-03-23 Institute Of Physical & Chemical Research Athlete's foot treatment equipment
SI3424932T1 (en) 2005-02-16 2021-08-31 Anacor Pharmaceuticals, Inc. Boronophthalides for therapeutic use
MX2007014439A (en) 2005-05-18 2008-02-11 Tyrell Inc Treatment device and method for treating skin lesions through application of heat.
US7793666B2 (en) 2005-07-28 2010-09-14 Innovation Biomedical Devices, Inc. Apparatus and method for treatment of infected nail
US20070104664A1 (en) 2005-10-26 2007-05-10 California Institute Of Technology Treatment of toenail fungus
CA2635680A1 (en) 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CA2651212A1 (en) 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2008157481A1 (en) 2007-06-15 2008-12-24 Transport Pharmaceuticals, Inc. Method and system for mitigating current concentration in electrokinetic drug delivery
US20090048590A1 (en) 2007-08-15 2009-02-19 Tyrell, Inc. Systems and methods for treating nail-bed fungus through application of heat
ES2324192B1 (en) * 2008-01-30 2010-06-17 PUIG BEAUTY & FASHION GROUP, S.L. PEPTIDIC DERIVATIVES USEFUL IN THE TREATMENT, CARE OR CLEANING OF THE SKIN, MUCOSA, LEATHER HAIR OR NAILS.
FR2942716B1 (en) * 2009-03-06 2011-04-15 Galderma Res & Dev METHOD FOR SOLUBILIZING ANTIFUNGAL AGENT AND COMPOSITIONS HAVING HIGH CONCENTRATION OF ANTIFUNGAL AGENT APPLICABLE ON THE NATIVE
IT1395241B1 (en) 2009-08-07 2012-09-05 Iarrera APPARATUS FOR SEEDED CONTROLLED GERMINATION AND ITS METHOD.
EP2544659A2 (en) 2009-12-23 2013-01-16 Nuvo Research Inc. Highly permeating terbinafine formulation for treating onychomycosis
CN103154252B (en) * 2010-08-23 2017-05-24 先锋国际良种公司 Novel defensin variants and methods of use
KR101311196B1 (en) * 2010-12-23 2013-09-27 중앙대학교 산학협력단 Use of IRE1 gene and HXL1 gene in UPR signal pathway for treating mycoses or meningoencephalitis
KR101947126B1 (en) * 2010-12-28 2019-02-13 카메디스 리미티드 Plant extracts for the treatment and prevention of infections
EP2664327A1 (en) 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
AR094821A1 (en) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION
AU2013260696A1 (en) * 2012-11-23 2014-06-12 Hexima Limited Use of anti-fungal defensins
CA2891989A1 (en) 2012-11-23 2014-05-30 Nicole Van Der Weerden Anti-pathogenic methods
AU2014231816B2 (en) 2013-03-12 2016-11-03 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
AU2015251499B2 (en) 2014-04-23 2018-08-09 Hexima Limited Agents and methods for treatment of pathogens
JP2017517498A (en) 2014-04-24 2017-06-29 ヘキシマ リミテッド Drugs and treatment methods
PL3209319T3 (en) 2014-10-21 2021-12-20 Hexima Limited A method of treatment of fungal infections

Also Published As

Publication number Publication date
CA2965187A1 (en) 2016-04-28
SI3209319T1 (en) 2022-01-31
JP6990224B2 (en) 2022-02-03
EP3209319B1 (en) 2021-07-14
SG11201703184SA (en) 2017-05-30
AU2021201810A1 (en) 2021-04-22
CY1124640T1 (en) 2022-07-22
JP2017533210A (en) 2017-11-09
JP2022022316A (en) 2022-02-03
EP3949977A1 (en) 2022-02-09
LT3209319T (en) 2021-10-25
ES2890461T3 (en) 2022-01-19
JP2020097573A (en) 2020-06-25
NZ731143A (en) 2021-07-30
CN118453831A (en) 2024-08-09
AU2021201810B2 (en) 2024-08-22
US20170296622A1 (en) 2017-10-19
HUE056178T2 (en) 2022-01-28
US11446354B2 (en) 2022-09-20
US9713632B2 (en) 2017-07-25
MY186552A (en) 2021-07-26
MX382906B (en) 2025-03-13
PL3209319T3 (en) 2021-12-20
US20210228678A1 (en) 2021-07-29
WO2016061619A1 (en) 2016-04-28
AU2015336933A1 (en) 2017-05-11
AU2015336933B2 (en) 2021-01-14
US20170239328A1 (en) 2017-08-24
US10010576B2 (en) 2018-07-03
CN113368215A (en) 2021-09-10
KR102472312B1 (en) 2022-11-29
US10973874B2 (en) 2021-04-13
PT3209319T (en) 2021-09-24
JP6646662B2 (en) 2020-02-14
CN107106647A (en) 2017-08-29
JP7207780B2 (en) 2023-01-18
CN107106647B (en) 2021-08-10
KR20170072291A (en) 2017-06-26
BR112017008211A2 (en) 2017-12-26
HRP20211477T8 (en) 2022-03-04
EP3209319A1 (en) 2017-08-30
HRP20211477T1 (en) 2022-01-07
SMT202100558T1 (en) 2021-11-12
RS62386B1 (en) 2021-10-29
MX2021006057A (en) 2021-07-06
MX2017005305A (en) 2017-08-02
DK3209319T3 (en) 2021-10-04
US20160106807A1 (en) 2016-04-21
EP3209319A4 (en) 2018-05-16

Similar Documents

Publication Publication Date Title
IL279627A (en) Method for the treatment of depression
GB201701673D0 (en) Methods of well treatment
EP3307286A4 (en) A method of treatment
GB201410116D0 (en) Method of treatment
GB201506175D0 (en) Method of treating a material
GB201401430D0 (en) Treatment process
GB2522719B (en) Method of manufacture
SG11201703184SA (en) A method of treatment
IL253028A0 (en) Method of treatment
GB201416832D0 (en) Methods of treatment
GB201521886D0 (en) A method of treating a well
GB2522716B (en) Method of manufacture
GB201416350D0 (en) A method of fitting
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201421982D0 (en) Method of treatment
GB201421980D0 (en) Method of treatment
GB2543449B (en) Method of completing a well
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment
AU2014905126A0 (en) A method of treatment
AU2014904978A0 (en) A method of treatment
AU2014904633A0 (en) A method of treatment
AU2014904211A0 (en) A method of treatment
AU2014904178A0 (en) A method of treatment
GB201423238D0 (en) A method of ambandoning a well